China smartphone shipments slumped in June on inventory overhang: Jefferies
Paul L. Alpern, Vice President and General Counsel of Arteris , Inc. (NASDAQ:AIP), has recently sold shares of the company. According to a filing with the Securities and Exchange Commission, Alpern sold 406 shares of Arteris common stock on March 6, 2025. The shares were sold at a price of $8.17 each, totaling approximately $3,317. The stock has since declined to $7.89, marking a significant 13.4% drop over the past week. InvestingPro data shows the company maintains impressive gross profit margins of nearly 90%.
Following this transaction, Alpern retains ownership of 90,204 shares. The sale was executed under a 10b5-1 trading plan, which Alpern adopted on May 8, 2024. This type of plan allows insiders of publicly traded corporations to set up a predetermined schedule for selling stocks they own. Despite recent price weakness, analysts maintain optimistic price targets ranging from $11 to $16 per share. Get deeper insights into AIP’s valuation and 7 additional key ProTips with InvestingPro’s comprehensive research report.
In other recent news, Arteris, Inc. has seen notable developments impacting its financial outlook and market perception. Jefferies analyst Blayne Curtis raised the company’s price target to $11 from $7, maintaining a Hold rating, citing Arteris’ progress in the microcontroller unit market, which includes a significant win at IFX. The introduction of the FlexGen solution is expected to increase the average selling price per license by 30%, potentially accelerating the company’s path to breakeven by 2025. Despite these advancements, Jefferies remains cautious, awaiting more evidence of improved execution in MCU and FlexGen license sales.
Meanwhile, Northland analysts have increased their price target for Arteris to $16 from $14, keeping an Outperform rating, following the successful launch of the new FlexGen product. Arteris reported revenue that met expectations, with bookings of approximately $33.6 million and a book-to-bill ratio of 2.2:1. The FlexNoC 5 product has also been successful, accounting for a significant portion of interconnect licenses. Northland’s increased price target reflects the anticipated positive impact of FlexGen on Arteris’ financial performance, with 13 customers currently evaluating the product.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.